L-T. Chen

发表

Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis.

J. Chang, C.-C. Chen, K.-J. Liu, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil

J. Chang, T. Tsou, C. Kuo, 2007, British Journal of Cancer.

A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer

Y. Chao, C. Yen, P. Lin, 2010, British Journal of Cancer.

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

M. Tempero, W. Su, Li‐Tzong Chen, 2013, British Journal of Cancer.

Differential response to H. pylori eradication therapy of co‐existing diffuse large B‐cell lymphoma and MALT lymphoma of stomach—significance of tumour cell clonality and BCL10 expression

K. Yeh, H. Hsu, P. Yeh, 2007, The Journal of pathology.

Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer

J. Chang, P. Chu, Y-C Lee, 2011, Oncogene.

Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance

K. Yeh, A. Cheng, S. Kuo, 2013, Blood Cancer Journal.

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients

I. Sheen, Y. Chao, J. Wang-Peng, 2010, British Journal of Cancer.

LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study

S. Oh, S. Sym, I. Chung, 2020 .

188 POSTER Combined modalities of resistance in an oxaliplaitin-resistant human gastric cancer cell line with enhanced sensitivity

J. Chang, T. Tsou, C. Kuo, 2006 .

ATTRACTION-05 (ONO-4538-38/BMS CA209844): a randomized, multicenter, double-blind, placebo-controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer

M. Sasako, H. Chung, M. Terashima, 2017 .

The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV).

B. Mirakhur, J. Siveke, T. Macarulla, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

741P Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone.

G. Bodoky, D. Cunningham, F. Braiteh, 2017 .

Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1.

T. Bekaii-Saab, B. Mirakhur, J. Blanc, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphoma

Chung-Wu Lin, A. Cheng, S. Kuo, 2014, Blood Cancer Journal.

alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.

J. Whang‐Peng, J. Chang, Y. Chao, 2005, Alimentary pharmacology & therapeutics.